CD5-directed chimeric antigen receptor engineered T-cells are engineered to express an anti-CD5scFV antibody domain. This autologous CAR derived from a patient’s own blood cells is in development for T-cell acute lymphoblastic leukemia. CD5CAR has been granted Orphan Drug Designation by the US Food and Drug Administration for the treatment of T-cell Acute Lympocytic Leukemia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!